Key facts
- This page summarizes Sanjay Subramanian's Form 4 filing for Ocugen, Inc. (OCGN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Dec 2021, 20:26.
Sanjay Subramanian - 16 Dec 2021 Form 4 Insider Report for Ocugen, Inc. (OCGN)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- OCGN
- Reported as of
- 16 Dec 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Dec 2021, 20:26:10 UTC
- Prior SEC filing
- 18 Nov 2021
- Next SEC filing
- 05 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Sanjay Subramanian
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sanjay Subramanian filed Form 4 for Ocugen, Inc. (OCGN) on 17 Dec 2021.
Change
- Previous filing in this sequence was filed on 18 Nov 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OCGN
transaction
Derivative
Option(Right toBuy)
Award
- Transaction value
- $0
- Shares
- +35,560
- Change %
- +100%
- Price
- $0.000000
- Shares after
- 71,120
- Date
- 16 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,560
- Exercise price
- $5.64
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the closing price of Ocugen, Inc.'s (the "Company") common stock on the date of grant. See footnote 2 below.
Footnote F2
On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 177,800 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the "Performance-Based Option"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a "Determination Date") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date.
Footnote F3
On December 16, 2021, the Compensation Committee determined that the second performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 35,560 shares. 17,780 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 17,780 shares vesting on December 16, 2022, subject to the Reporting Person's continued service with the Company.